Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

32.08 +1.15 (+3.70%)

Streaming Delayed Price Updated: 3:26 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

US Stocks Open Lower; Nasdaq Drops 100 Points ↗

November 03, 2022

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Thursday. The Federal Reserve, on Wednesday, raised interest rates by 75 bps.

Via Benzinga

Veracyte Announces Third Quarter 2022 Financial Results

November 02, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

November 01, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

October 27, 2022

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For November 2, 2022 ↗

November 02, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.

Via Benzinga

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

October 25, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

October 24, 2022

From Veracyte, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 19, 2022

Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.

Via Benzinga

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

October 18, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

October 13, 2022

From Veracyte, Inc.

Via Business Wire

New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

September 22, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

September 13, 2022

From Veracyte, Inc.

Via Business Wire

New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

September 11, 2022

From Veracyte, Inc.

Via Business Wire

New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

September 07, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 01, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

August 31, 2022

From Veracyte, Inc.

Via Business Wire

New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

August 29, 2022

From Veracyte, Inc.

Via Business Wire

Whither Small Caps After Fed’s Tough Talk? ↗

August 29, 2022

For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...

Via Talk Markets

Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

August 11, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte: Q2 Earnings Insights ↗

August 02, 2022

Veracyte (NASDAQ:VCYT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by...

Via Benzinga

Veracyte Announces Second Quarter 2022 Financial Results

August 02, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte's Earnings: A Preview ↗

August 01, 2022

Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will...

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid

July 20, 2022

From Veracyte, Inc.

Via Business Wire

Small Cap Biotech Stocks Are Trending Well ↗

July 18, 2022

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Via Talk Markets

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

July 14, 2022

From Veracyte, Inc.

Via Business Wire

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

July 13, 2022

From Veracyte, Inc.

Via Business Wire

Small Cap Biotechs Regain Momentum ↗

July 11, 2022

Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values.

Via Talk Markets

Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year

June 27, 2022

From Veracyte, Inc.

Via Business Wire

Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗

June 22, 2022

Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.

Via Talk Markets

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.